Gert August Paul Caspritz
Corporate Officer/Principal chez Neomed Management (Jersey) Ltd.
Profil
Gert August Paul Caspritz is currently a Partner at Neomed Management (Jersey) Ltd.
He previously held positions as Chairman at Harbinger Medical, Inc., Director at Enanta Pharmaceuticals, Inc. and TransMolecular, Inc., and General Partner at TVM Capital Corp.
He also served as a Director at Weifa ASA and was a Principal at Hoechst AG.
Caspritz earned a doctorate degree from The Johannes Gutenberg University of Mainz in 1981.
Postes actifs de Gert August Paul Caspritz
| Sociétés | Poste | Début |
|---|---|---|
Neomed Management (Jersey) Ltd.
 Neomed Management (Jersey) Ltd. Investment ManagersFinance Neomed Management (Jersey) Ltd. is an investment firm invests in innovative healthcare and life science companies. The company is headquartered in St. Helier, the United Kingdom. | Corporate Officer/Principal | 15/06/2009 |
Anciens postes connus de Gert August Paul Caspritz
| Sociétés | Poste | Fin |
|---|---|---|
| WEIFA ASA | Directeur/Membre du Conseil | 20/05/2010 |
TVM Capital Corp.
 TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 30/10/2008 |
EpiCept Corp.
 EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Directeur/Membre du Conseil | 06/03/2008 |
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Corporate Officer/Principal | 31/12/1998 |
Harbinger Medical, Inc.
 Harbinger Medical, Inc. Medical DistributorsDistribution Services Harbinger Medical, Inc. developed diagnostic tools. It was a venture backed medical device that developed a non-invasive risk stratification system. The company was founded in 1992 and was headquartered in Eden Prairie, MN. | Président | - |
Formation de Gert August Paul Caspritz
| The Johannes Gutenberg University of Mainz | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
TransMolecular, Inc.
 TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
Hoechst AG
Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Health Technology |
TVM Capital Corp.
TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Finance |
Harbinger Medical, Inc.
Harbinger Medical, Inc. Medical DistributorsDistribution Services Harbinger Medical, Inc. developed diagnostic tools. It was a venture backed medical device that developed a non-invasive risk stratification system. The company was founded in 1992 and was headquartered in Eden Prairie, MN. | Distribution Services |
Neomed Management (Jersey) Ltd.
Neomed Management (Jersey) Ltd. Investment ManagersFinance Neomed Management (Jersey) Ltd. is an investment firm invests in innovative healthcare and life science companies. The company is headquartered in St. Helier, the United Kingdom. | Finance |
Weifa ASA
 Weifa ASA Pharmaceuticals: MajorHealth Technology Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway. | Health Technology |
